Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.50 Contact Hours.
Acknowledgment of Commercial Support
This activity is supported by educational grants from Genentech, Inc.; Janssen Pharmaceuticals; Eli Lilly and Company; and Pharmacyclics LLC, an AbbVie Company.
Community Practice Connections™: How Are We Meeting the Needs of Patients With CLL Across Lines of Care?
Release Date: November 30, 2021
Expiration Date: November 30, 2022
Activity Overview
This Community Practice Connections™ program provides an in-depth review of some of the key highlights from the recent virtual satellite symposium, How Are We Meeting the Needs of Patients With CLL Across Lines of Care? held in September 2021. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects managing patients with CLL, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the virtual symposium and to help reinforce learnings for those who did.
Acknowledgement of Commercial Support
This activity is supported by educational grants from Genentech, Inc.; Janssen Pharmaceuticals; Eli Lilly and Company; and Pharmacyclics LLC, an AbbVie Company.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate. |
Target Audience
Learning Objectives
At the conclusion of this activity, you should be better prepared to:
- Determine risk stratification methods in patients with CLL and application of patient risk categories for treatment identification
- Integrate evolving practices in the management of patients with CLL through multiple lines of therapy, integrating the influence of previous regimens on subsequent decision-making
- Discuss the role of minimal residual–disease (MRD) testing as a tool for prognosis and treatment selection in patients with CLL
- Evaluate strategies to proactively mitigate and manage treatment-related adverse events that occur with current and emerging approaches, including combination treatment strategies
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
Faculty
Director, CLL Program
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Grant/Research Support: TG Therapeutics, Pharmacyclics, Adaptive Biotechnologies, AbbVie, Acerta Pharma/AstraZeneca, Sunesis Pharmaceuticals, Loxo Oncology, Regeneron Pharmaceuticals, DTRM; Consultant: TG Therapeutics, Pharmacyclics, Adaptive Biotechnologies, AbbVie, Acerta Pharma/AstraZeneca, Sunesis Pharmaceuticals, Loxo Oncology, Regeneron Pharmaceuticals, Johnson & Johnson, Celgene; Other: Advisory Board: Data and Safety Monitoring Board: TG Therapeutics, Celgene.
Associate Professor of Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Grant/Research Support: Pharmacyclics, AbbVie, Genentech, AstraZeneca, Bristol Myers Squibb, Pfizer, ADC Therapeutics, Incyte, Servier, Cellectis, Adaptive Biotechnologies, Precision BioSciences, Aprea Therapeutics, Fate Therapeutics; Consultant: Pharmacyclics, Janssen Pharmaceuticals, AbbVie, Genentech, AstraZeneca, Adaptive Biotechnologies, Laboratoires Servier, Precision BioSciences, BeiGene, TG Therapeutics, ADC Therapeutics.
DB Lane Cancer Research Distinguished Professor
Section Chief, Chronic Lymphocytic Leukemia
Center Medical Director
Department of Leukemia, Division of Cancer Medicine
Executive Medical Director, Inpatient Medical Services
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Grant/Research support: GlaxoSmithKline/Novartis, AbbVie, Genentech, Pharmacyclics, Acerta Pharma/AstraZeneca, Gilead Sciences, Juno Therapeutics, Kite Pharma, Sunesis Pharmaceuticals, Miragen Therapeutics, Oncternal Therapeutics, Cyclacel Pharmaceuticals, Loxo Oncology, Janssen Pharmaceuticals, Xencor.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.